Oligonucleotide CDMO Market Size to Reach USD 15,071.7 Million in 2032
The Oligonucleotide CDMO Market size was USD 2,883.2 Million in 2024 and is expected to register a revenue CAGR of 22.9% during the forecast period
June 01st, 2025 – Rising demand for oligonucleotide-based therapeutics is a key driver driving oligonucleotide CDMO market revenue growth. Oligonucleotide synthesis has evolved as a key component of modern biotechnology, with applications ranging from medication development to genetic research. As the need for more personalized treatments and advanced cures rises, oligonucleotides play an increasingly essential role in the pharmaceutical and biotech industries.
On May 2024, Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off of General Biol Co., Ltd, will provide the world with cGMP-level oligonucleotide (oligo) CRDMO services via Cytiva’s first FlexFactory platform for oligo manufacturing. Ribobay Pharma may better serve their clients by leveraging the FlexFactory platform, which includes process development support, optimization, method development, pilot production services, and customized manufacturing.
Oligonucleotide manufacture, especially on a commercial scale, presents significant efficiency issues. These issues are motivated by both financial and technical considerations. The high cost of raw materials necessary for oligonucleotide synthesis is one of the key causes of high production costs. High-purity reagents and specific solvents are required to ensure nucleotide incorporation integrity during synthesis. Longer and more complicated oligos necessitate more expensive reagents.
Key Highlights:
- Small interfering RNA (siRNA) segment is expected to register the largest market share over the forecast period. Small interfering RNAs (siRNAs) have developed as new nucleic acid therapeutics for the treatment of life-threatening disorders including cancer. Researchers conducting RNAi studies have identified that synthetic small interfering RNAs (siRNA) or short hairpin RNAs (shRNA) hold clinical potential for treating dental diseases, eye infections, cancer, metabolic syndromes, neurological disorders, and other ailments. Another advantage of siRNA as a therapeutic agent is its ability to silence a wide range of target proteins to treat various conditions.
- Neurological disorders segment is expected to account for the largest growth rate over the forecast period. ALS, or amyotrophic lateral sclerosis, affects nerve cells that control muscle function. As a result, muscles begin to deteriorate, creating weakness. Every year, approximately 1.7 to 2.2 out of every 100,000 persons are diagnosed with ALS. Given these figures, it is considered a rare sickness in the context of other health disorders.
- North America accounted for the largest market revenue share in the oligonucleotide CDMO market in 2024 due to rising demand for oligonucleotide-based therapeutics and technological advancements in oligonucleotide synthesis. On January 2023, Agilent Technologies Inc. has stated that it will invest roughly USD 725 million to increase therapeutic nucleic acid manufacturing capacity in response to the rapidly growing USD 1 billion industry and strong demand for the company’s high-quality active pharmaceutical ingredients (API). Therapeutic nucleic acids, also known as therapeutic oligonucleotides or oligos, are small DNA and RNA molecules that act as the active pharmaceutical ingredient (API) for medications used to treat a growing array of disorders, including cancer, cardiovascular disease, uncommon and infectious diseases.
- Some major companies in the market report include CordenPharma, Kaneka Eurogentec S.A, ST Pharm, Veliter, Sylentis S.A, EUROAPI, BOC Sciences, Agilent Technologies, Inc., Lonza, Bachem Group, NIPPON SHOKUBAI CO., LTD., TAPI, Syngene International Limited, CPC Scientific Inc., and Aurisco.
- On June 2024, Suven Pharmaceuticals Limited, India’s largest integrated CDMO, has agreed to make a strategic controlling investment in Sapala Organics Private Limited, subject to regulatory approvals. Sapala is one of the few worldwide players with extensive knowledge in many specialized building components. Sapala partners with innovative Pharma, CDMOs, and diagnostic firms to support their Oligo drug NCE campaigns.
Unlock the key to transforming your business strategy with our Oligonucleotide CDMO insights:
Navistrat Analytics has segmented Oligonucleotide CDMO market size based on product type, service type, synthesis scale, and indication:
- Product Type Outlook (Revenue, USD Million; 2022-2032)
- Antisense Oligonucleotides (ASOs)
- Small Interfering RNA (siRNA)
- Aptamers
- DNA Oligonucleotides
- RNA Oligonucleotides
- miRNA
- Service Type Outlook (Revenue, USD Million; 2022-2032)
- Custom Oligonucleotide Synthesis
- Process Development & Optimization
- Analytical Services
- Manufacturing Services
- Others
- Synthesis Scale Outlook (Revenue, USD Million; 2022-2032)
- Clinical Stage
- Commercial Stage
- Indication Outlook (Revenue, USD Million; 2022-2032)
- Oncology
- Rare & Genetic Disorders
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Ophthalmic Diseases
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America